TherapeuticsMD Company Profile (NYSEMKT:TXMD)

About TherapeuticsMD (NYSEMKT:TXMD)

TherapeuticsMD logoTherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:TXMD
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $811.63 million
  • Outstanding Shares: 203,927,000
Average Prices:
  • 50 Day Moving Avg: $4.91
  • 200 Day Moving Avg: $5.91
  • 52 Week Range: $3.50 - $9.29
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -44.22
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $18.41 million
  • Price / Sales: 44.09
  • Book Value: $0.56 per share
  • Price / Book: 7.11
Profitability:
  • EBIDTA: ($90,400,000.00)
Misc:
  • Average Volume: 3.48 million shs.
  • Short Ratio: 32.39
 

Frequently Asked Questions for TherapeuticsMD (NYSEMKT:TXMD)

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NYSEMKT:TXMD) released its earnings results on Thursday, November, 3rd. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The firm earned $5.50 million during the quarter, compared to the consensus estimate of $5.76 million. The company's revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.11) earnings per share. View TherapeuticsMD's Earnings History.

Where is TherapeuticsMD's stock going? Where will TherapeuticsMD's stock price be in 2017?

7 brokers have issued 1-year target prices for TherapeuticsMD's shares. Their forecasts range from $10.50 to $33.00. On average, they anticipate TherapeuticsMD's stock price to reach $20.57 in the next year. View Analyst Ratings for TherapeuticsMD.

What are analysts saying about TherapeuticsMD stock?

Here are some recent quotes from research analysts about TherapeuticsMD stock:

  • 1. Jefferies Group LLC analysts commented, "TXMD and its expert speakers/consultants made convincing cases for TX-001 and '004 as differentiated and needed HRTs for VMS/VVA. With strong senior talent and sound marketing strategies, we believe '004 can take meaningful share (even without a clean label with no boxed safety warnings), while '001 can become the new standard of care, especially in the compounding pharmacy channel (with no competition). TXMD remains a top 2017 small-cap pick." (3/2/2017)
  • 2. According to Zacks Investment Research, "TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. " (2/25/2017)

Who are some of TherapeuticsMD's key competitors?

How do I buy TherapeuticsMD stock?

Shares of TherapeuticsMD can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of TherapeuticsMD stock cost?

One share of TherapeuticsMD stock can currently be purchased for approximately $3.98.

Analyst Ratings

Consensus Ratings for TherapeuticsMD (NYSEMKT:TXMD) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $20.57

Analysts' Ratings History for TherapeuticsMD (NYSEMKT:TXMD)
Show:
DateFirmActionRatingPrice TargetDetails
5/25/2017Stifel NicolausReiterated RatingBuy$20.00View Rating Details
5/11/2017Cantor FitzgeraldReiterated RatingOverweight$33.00View Rating Details
5/9/2017Oppenheimer Holdings Inc.DowngradeOutperform -> Market Perform$12.00View Rating Details
3/2/2017Jefferies Group LLCReiterated RatingBuy$18.00View Rating Details
12/6/2016GuggenheimReiterated RatingPositiveView Rating Details
12/4/2016Goldman Sachs Group IncReiterated RatingBuy$10.50View Rating Details
7/11/2016Noble FinancialReiterated RatingBuy$17.50View Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for TherapeuticsMD (NYSEMKT:TXMD)
Earnings by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Earnings History by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017Q416($0.12)($0.12)$5.91 million$4.49 millionViewListenView Earnings Details
11/3/2016Q316($0.11)($0.13)$5.76 million$5.50 millionViewN/AView Earnings Details
8/4/2016Q216($0.10)($0.11)$5.63 million$4.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.09)($0.11)$5.73 million$4.93 millionViewN/AView Earnings Details
2/25/2016Q415($0.10)($0.10)$5.33 million$5.63 millionViewListenView Earnings Details
11/4/2015Q315($0.12)($0.11)$5.01 million$5.19 millionViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.16)$4.65 million$4.80 millionViewListenView Earnings Details
5/5/2015($0.10)($0.13)ViewN/AView Earnings Details
3/10/2015Q414($0.09)($0.10)$2.86 million$4.26 millionViewN/AView Earnings Details
11/6/2014Q3 14($0.08)($0.12)ViewN/AView Earnings Details
5/6/2014Q1 14($0.06)($0.06)$3.08 million$2.80 millionViewN/AView Earnings Details
3/3/2014Q213($0.06)($0.06)$2.72 million$2.90 millionViewN/AView Earnings Details
5/8/2013Q113($0.06)($0.06)$1.32 million$1.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TherapeuticsMD (NYSEMKT:TXMD)
Current Year EPS Consensus Estimate: $-0.45 EPS
Next Year EPS Consensus Estimate: $-0.09 EPS

Dividends

Dividend History for TherapeuticsMD (NYSEMKT:TXMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TherapeuticsMD (NYSEMKT:TXMD)
Insider Trades by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Institutional Ownership by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Insider Trades by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/11/2016Cooper C CollinsDirectorBuy16,000$6.23$99,680.00View SEC Filing  
8/25/2015Angus C RussellDirectorBuy13,500$5.98$80,730.00View SEC Filing  
6/8/2015Mitchell KrassanEVPSell30,000$8.18$245,400.00View SEC Filing  
5/12/2015Angus C RussellDirectorBuy35,000$6.15$215,250.00View SEC Filing  
5/11/2015Tommy G ThompsonChairmanBuy6,000$6.09$36,540.00View SEC Filing  
5/8/2015J Martin CarrollDirectorBuy10,000$6.11$61,100.00View SEC Filing  
11/21/2014Daniel A CartwrightCFOSell40,000$3.91$156,400.00View SEC Filing  
9/4/2014Tommy G ThompsonDirectorBuy1,757$5.44$9,558.08View SEC Filing  
6/5/2014Cooper C CollinsDirectorBuy20,000$3.84$76,800.00View SEC Filing  
5/9/2014Robert Lapenta, Jr.DirectorBuy5,000$3.66$18,300.00View SEC Filing  
5/8/2014Tommy ThompsonDirectorBuy14,000$3.57$49,980.00View SEC Filing  
3/26/2014Brian BernickDirectorSell421,268$6.70$2,822,495.60View SEC Filing  
3/26/2014John C.K. Iv MilliganInsiderSell353,412$6.70$2,367,860.40View SEC Filing  
3/26/2014Robert FinizioCEOSell982,053$6.70$6,579,755.10View SEC Filing  
3/10/2014Mitchell KrassanEVPSell7,500$7.73$57,975.00View SEC Filing  
2/26/2014John C.K. Iv MilliganPresidentSell25,000$6.31$157,750.00View SEC Filing  
2/21/2014Robert FinizioCEOSell50,000$6.17$308,500.00View SEC Filing  
2/12/2014Brian BernickDirectorSell31,250$6.16$192,500.00View SEC Filing  
1/30/2014John C.K. Iv MilliganInsiderSell25,000$6.16$154,000.00View SEC Filing  
1/23/2014Robert G FinizioCEOSell50,000$5.70$285,000.00View SEC Filing  
1/13/2014Mitchell KrassanEVPSell7,500$5.73$42,975.00View SEC Filing  
1/8/2014Brian BernickDirectorSell31,250$5.13$160,312.50View SEC Filing  
8/26/2013Brian BernickInsiderSell1,600,000$1.55$2,480,000.00View SEC Filing  
8/26/2013Jules A MusingDirectorBuy5,282$2.15$11,356.30View SEC Filing  
6/14/2013Cooper C CollinsDirectorSell2,631,579$1.75$4,605,263.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for TherapeuticsMD (NYSEMKT:TXMD)
Latest Headlines for TherapeuticsMD (NYSEMKT:TXMD)
Source:
DateHeadline
globenewswire.com logoIMPORTANT THERAPEUTICSMD, INC. INVESTOR REMINDER: Wolf Haldenstein Adler ...
globenewswire.com - May 26 at 8:04 AM
finance.yahoo.com logoTXMD INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017
finance.yahoo.com - May 26 at 8:04 AM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - May 25 at 1:21 PM
finance.yahoo.com logoTherapeuticsMD Announces Presentation at Jefferies 2017 Healthcare Conference on June 8
finance.yahoo.com - May 23 at 7:47 PM
finance.yahoo.com logoEQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 23 at 7:47 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Complaint to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. and Sets Lead Plaintiff Deadline of June 19, 2017 - TXMD
finance.yahoo.com - May 22 at 7:21 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Complaint to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. -- Sets Lead Plaintiff Deadline of June 19, 2017 -- TXMD
finance.yahoo.com - May 18 at 11:40 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Complaint to Recover Losses Suffered by Investors in TherapeuticsMD, Inc.
finance.yahoo.com - May 17 at 8:59 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 17 at 8:59 PM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) and Lead Plaintiff Deadline: June 19, 2017
finance.yahoo.com - May 17 at 12:22 PM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 15 at 9:38 AM
finance.yahoo.com logoTXMD SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017
finance.yahoo.com - May 12 at 2:54 AM
finance.yahoo.com logoEQUITY ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 12 at 2:54 AM
americanbankingnews.com logoTherapeuticsMD's (TXMD) Overweight Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - May 11 at 4:20 PM
prnewswire.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TherapeuticsMD, Inc ... - PR Newswire (press release)
www.prnewswire.com - May 11 at 2:35 AM
fool.com logoHere's Why TherapeuticsMD Inc. Stock Is Sinking Today - Motley Fool
www.fool.com - May 9 at 7:54 PM
finance.yahoo.com logoToday's on Research Reports on Biotech Stocks to Watch: TherapeuticsMD and MannKind
finance.yahoo.com - May 9 at 9:53 AM
finance.yahoo.com logoTherapeuticsMD Results 'Worse Than Expected'
finance.yahoo.com - May 8 at 7:52 PM
finance.yahoo.com logoHere's Why TherapeuticsMD Inc. Stock Is Sinking Today
finance.yahoo.com - May 8 at 7:52 PM
finance.yahoo.com logoTXMD SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017
finance.yahoo.com - May 8 at 7:52 PM
finance.yahoo.com logoLaw Offices of Howard G. Smith Reminds TherapeuticsMD, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
finance.yahoo.com - May 8 at 7:52 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 8 at 7:52 PM
fool.com logoHere's Why TherapeuticsMD Inc. Stock Is Sinking Today
www.fool.com - May 8 at 1:43 PM
streetinsider.com logoTherapeuticsMD (TXMD) Receives CRL from FDA for TX-004HR NDA - StreetInsider.com
www.streetinsider.com - May 8 at 9:33 AM
nasdaq.com logoTXMD All Set For D-day, IMMU Soars On Strategic Plan, CTSO On Watch - Nasdaq
www.nasdaq.com - May 7 at 9:56 PM
feeds.benzinga.com logoWill TherapeuticsMD's Yuvvexy Pass The FDA Muster?
feeds.benzinga.com - May 7 at 4:02 PM
finance.yahoo.com logoETFs with exposure to TherapeuticsMD, Inc. : May 5, 2017
finance.yahoo.com - May 5 at 11:43 PM
finance.yahoo.com logoTherapeuticsMD, Inc. :TXMD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
finance.yahoo.com - May 5 at 2:28 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Filing to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. and Sets Lead Plaintiff Deadline of June 19, 2017 -- TXMD
finance.yahoo.com - May 5 at 2:28 AM
finance.yahoo.com logoTherapeuticsMD reports 1Q loss
finance.yahoo.com - May 3 at 10:05 AM
finance.yahoo.com logoLawsuit for Investors in (NYSE MKT: TXMD) Shares Against TherapeuticsMD Inc. Announced by Shareholders ... - Yahoo Finance
finance.yahoo.com - May 1 at 7:30 PM
finance.yahoo.com logoLawsuit for Investors in (NYSE MKT: TXMD) Shares Against TherapeuticsMD Inc. Announced by Shareholders Foundation
finance.yahoo.com - May 1 at 7:30 PM
finance.yahoo.com logoGlancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of TherapeuticsMD, Inc. Investors and Encourages Investors to Contact the Firm
finance.yahoo.com - May 1 at 7:30 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Filing to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. and Sets Lead Plaintiff Deadline of June 19, 2017 -- TXMD
finance.yahoo.com - May 1 at 7:30 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - April 29 at 9:05 AM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - April 27 at 10:13 PM
finance.yahoo.com logoTXMD INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017
finance.yahoo.com - April 27 at 10:13 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) and Lead Plaintiff Deadline: June 19, 2017
finance.yahoo.com - April 27 at 10:47 AM
finance.yahoo.com logoRM LAW Announces Class Action Lawsuit Against TherapeuticsMD, Inc.
finance.yahoo.com - April 26 at 9:53 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - April 26 at 9:53 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against TherapeuticsMD, …
finance.yahoo.com - April 25 at 7:20 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) & Lead Plaintiff Deadline: June 19, 2017
finance.yahoo.com - April 25 at 7:20 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Filing to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. -- Sets Lead Plaintiff Deadline of June 19, 2017 -- TXMD
finance.yahoo.com - April 25 at 7:20 PM
finance.yahoo.com logoINVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit Against TherapeuticsMD, Inc.
finance.yahoo.com - April 25 at 7:20 PM
americanbankingnews.com logoTherapeuticsMD's (TXMD) "Buy" Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - April 25 at 6:54 PM
nasdaq.com logoAre Options Traders Betting on a Big Move in TherapeuticsMD (TXMD) Stock? - Nasdaq
www.nasdaq.com - April 25 at 9:04 AM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in TherapeuticsMD (TXMD) Stock?
finance.yahoo.com - April 24 at 9:43 AM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Given Overweight Rating at Cantor Fitzgerald
www.americanbankingnews.com - April 22 at 7:46 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - April 21 at 8:12 PM
globenewswire.com logoIMPORTANT THERAPEUTICSMD, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman ...
globenewswire.com - April 21 at 10:20 AM

Social

This page was last updated on 5/26/2017 by MarketBeat.com Staff